MEDICLINIC INTERNATIONAL PLC - Directorate changes - Appointment of Dr Anja Oswald as an independent non-executive director

Release Date: 25/07/2018 15:45
Code(s): MEI
 
Wrap Text
Directorate changes - Appointment of Dr Anja Oswald as an independent non-executive director

Mediclinic International plc
(Incorporated in England and Wales)
Company Number 8338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
("Mediclinic" or "the Company")

25 July 2018

DIRECTORATE CHANGES

APPOINTMENT OF DR ANJA OSWALD AS AN INDEPENDENT NON-EXECUTIVE DIRECTOR

Mediclinic announces that Dr Anja Oswald is to join its Board as an independent non-executive director
with effect from 25 July 2018.

Dr Edwin Hertzog, Chairman of Mediclinic, commented:

"The Board is delighted to welcome Dr Oswald as an independent non-executive director of the
Company. Her expertise in the Swiss healthcare system, health politics and the regulatory environment,
surgical medicine, general management and the development of business strategies will be valuable
additions to the Board."

Dr Oswald is the CEO of the Klinik Sonnenhalde, a well-established private clinic for psychiatry and
psychotherapy with inpatients, day-care clinics and outpatients in Riehen, Switzerland and is Vice-
President of the Association of Private Hospitals in Basel. Prior to this, she was Head of Medical and
Pharmaceutical Services and Deputy Medical Officer in the Department of Health of the Cantonal
Government in Basel and a member of various cantonal, regional and national committees. Dr Oswald
was also CEO of a start-up company in the health care sector and worked several years as a Medical
Doctor in different hospitals.

Dr Oswald holds a Masters in Business Administration from the Rochester-Berne Executive MBA, a
Doctorate in Medicine from the University of Basel specialising in orthopaedic surgery and traumatology
as well as in sports medicine. She passed the Board School at the International Centre of Corporate
Governance of the University of St. Gallen.

There are no disclosures required pursuant to paragraphs (1) to (6) of LR 9.6.13 R of the UK Listing
Authority's Listing Rules in respect of this appointment. Dr Oswald’s fees will amount to £80,000 per
annum, including the fees payable for committee memberships referred to in more detail below, which
is in line with current independent non-executive directors.

CHANGES TO COMMITTEE MEMBERSHIPS

The Board also agreed to certain other changes to the membership of its committees. As announced
on 29 March 2018, following the resignations of Ms Nandi Mandela and Prof Dr Robert Leu as
independent non-executive directors at the conclusion of the Annual General Meeting to be held today,
their memberships of all Board committees will cease at that point. Accordingly, the Company confirms
the following Board committee changes:

Remuneration Committee:
With effect from 25 July 2018, Prof Dr Robert Leu will step down as a member of the Remuneration
Committee and Dr Anja Oswald will be appointed as a member of the Remuneration Committee.

Nomination Committee:
With effect from 25 July 2018, Prof Dr Robert Leu and Mr Trevor Petersen will step down as members
of the Nomination Committee and will be replaced on that committee by Dr Felicity Harvey and Dr Anja
Oswald.

Clinical Performance and Sustainability Committee:
With effect from 25 July 2018, Prof Dr Robert Leu, Mr Danie Meintjes and Ms Nandi Mandela will step
down as members of the Clinical Performance and Sustainability Committee. Mr Seamus Keating and
Dr Ronnie van der Merwe will become members of the Clinical Performance and Sustainability
Committee from that date.

Investment Committee:
With effect from 25 July 2018, Mr Seamus Keating will step down as a member of the Investment
Committee and Dr Ronnie van der Merwe will be appointed as a member of the Investment Committee.

About Mediclinic International plc
Mediclinic is an international private healthcare services group with operating divisions in Switzerland,
Southern Africa (South Africa and Namibia) and the United Arab Emirates. Its core purpose is to
enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary
healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, an LSE-listed
and UK-based private healthcare group.

Mediclinic comprises 75 hospitals and 30 clinics. Hirslanden operates 17 private acute care facilities
and 4 clinics in Switzerland with more than 1 800 inpatient beds; Mediclinic Southern Africa operates
49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 100
inpatient beds in total; and Mediclinic Middle East operates 6 hospitals and 24 clinics with more than
700 inpatient beds in the United Arab Emirates.

Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary
listings on the JSE in South Africa and the NSX in Namibia.

For further information, please contact:

Company Secretary, Link Company Matters Limited
Jayne Meacham / Caroline Emmet
+44 (0)20 7954 9569

Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181

Media queries
FTI Consulting
Brett Pollard/Debbie Scott – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker: Morgan Stanley & Co International plc
JSE sponsor: RAND MERCHANT BANK (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd

Date: 25/07/2018 03:45:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

Email this JSE Sens Item to a Friend.

Share This Story